NANOCARRIER BASED INTRALYMPHATIC IMAGING AND THERAPY FOR MELANOMA

基于纳米载体的淋巴内成像和黑色素瘤治疗

• 批准号: 7959404
• 负责人: Mark Steven Cohen
• 金额: $ 14.1万
• 依托单位: UNIVERSITY OF KANSAS LAWRENCE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-03-01 至 2010-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7959404
• 关键词: Cancer Center; Computer Retrieval of Information on Scientific Projects Database; Contrast Media; Cutaneous Melanoma; Disease; Drops; Drug Delivery Systems; Funding; Gadolinium; Goals; Grant; Hyaluronic Acid; Image; Institution; Lymphatic; Magnetic Resonance Imaging; Melphalan; Methods; Modality; Morbidity - disease rate; Nanotechnology; Neoplasm Metastasis; Organ; Pharmaceutical Preparations; Research; Research Personnel; Resources; Site; Skin; Skin Cancer; Source; Staging; Survival Rate; System; Therapeutic; Toxic effect; United States National Institutes of Health; base; cancer imaging; falls; improved; lymph nodes; melanoma; nanocarrier; novel; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The rate of melanoma skin cancer is increasing yearly with 60000 new cases in 2007 in the US alone. Melanoma is highly curable if treated before it has spread from the primary site on the skin, but 5-year survival rates drop to only 29% once disease has spread to lymph nodes and fall even lower (down to 7%) if tumors metastasize to major organs. The goal of this proposal is to devetop and optimize a new drug-delivery and imaging platform for melanoma staging and treatment. Since melanomas naturally spread initially through local lymphatic channels and lymph nodes, this delivery and imaging system will specifically target the lymphatics. Using nanotechnology, hyaluronic acid, a compound naturally found in the body, is combined with drugs like melphalan normally used in regional therapy for melanoma, and delivered through the lymphatics. By lymphatic drug-delivery, the tumor is treated in a targeted manner, decreasing the amount of drug absorbed systemically which should result in a lower toxicity profile than the way it is currently administered. In addition to treating early melanoma through the lymphatics, this nanocarrier can be combined with gadolinium and imaged by MRI. Utilizing intralyrnphatic delivery for a contrast agent, this proposal will also explore novel ways to image lymphatically spread tumors such as melanoma. If successful, this research will result in an improved method for treating and imaging early to intermediate stage melanoma avoiding the morbidity of current treatment modalities and advancing the field of cancer imaging and therapeutics for lymphatically spread tumors.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 黑色素瘤皮肤癌的发病率逐年上升，仅在美国 2007 年就有 60,000 例新病例。如果在黑色素瘤从皮肤上的原发部位扩散之前进行治疗，其治愈率很高，但一旦疾病扩散到淋巴结，5 年生存率就会下降至 29%，如果肿瘤转移到淋巴结，则 5 年生存率会下降至更低（低至 7%）。主要机关。该提案的目标是开发和优化用于黑色素瘤分期和治疗的新药物输送和成像平台。由于黑色素瘤自然 最初通过局部淋巴管和淋巴结扩散，该输送和成像系统将专门针对淋巴管。利用纳米技术，透明质酸（一种体内天然存在的化合物）与马法兰等药物相结合 通常用于黑色素瘤的区域治疗，并通过淋巴管输送。 通过淋巴药物输送，以有针对性的方式治疗肿瘤，减少全身吸收的药物量，这将导致比目前给药方式更低的毒性。除了通过淋巴管治疗早期黑色素瘤外，这种纳米载体还可以与钆结合并通过 MRI 成像。利用淋巴管内输送造影剂，该提案还将探索对淋巴扩散肿瘤（如黑色素瘤）进行成像的新方法。如果成功，这项研究将带来一种改进的早期至中期黑色素瘤的治疗和成像方法，避免当前治疗方式的发病率，并推进癌症成像和淋巴扩散肿瘤治疗领域的发展。